Esophageal Achalasia Clinical Trial
Official title:
Safety, Efficacy and Cost-effectiveness of Snare-assisted POEM for Treatment of Esophageal Achalasia
NCT number | NCT02999451 |
Other study ID # | 123 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2017 |
Est. completion date | December 31, 2019 |
Verified date | June 2020 |
Source | First Affiliated Hospital, Sun Yat-Sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
POEM is a new intervention for the treatment of achalasia and has been reported to relieve the dysphagia symptom effectively. Although the cost of POEM method is less than the method of Laparoscopic Heller Myotomy and Fundoplication, it is still of an economic burden for the patients with achalasia. In this trial, investigators plan to use snare to assist POEM procedure, to observe the safety, efficacy and cost-effectiveness of this method, compared with other knifes-assisted procedure.
Status | Completed |
Enrollment | 75 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age between 18-70 years - Diagnosed as achalasia base on high resolution manometry, barium esophagram and Upper endoscopy - Signed written informed consent Exclusion Criteria: - ASA class > ? - Previous endoscopic or surgical treatment for achalasia - Esophageal malignancy - Pregnant |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital, Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical success rates | Clinical success is defined as a post-POEM Eckardt score =3 without additional treatment (Eckardt AJ et al, Nat Rev Gastroenterol Hepatol 2011). | 12 months after treatment | |
Secondary | Procedure-related adverse events | Adverse events are defined and graded according to the American Society for Gastrointestinal Endoscopy lexicon (Cotton PB et al, Gastrointest Endosc 2010). Incidental findings of pneumoperitoneum, pneumothorax, pneumomediastinum, pleural effusion on postoperative imaging, and subcutaneous emphysema were documented while not considered as adverse events. | baseline to 12 months after treatment | |
Secondary | Procedure time | Procedure time is measured from the start of submucosal injection until mucosal entry closure. | POEM procedure | |
Secondary | The volume of intraoperative bleeding | POEM procedure | ||
Secondary | The use of hemostatic forceps | POEM procedure | ||
Secondary | Postoperative pain requiring the use of tramadol | Pain related to POEM procedure requiring the use of tramadol pain medication. | Through hospital stay after procedure, an average of 2-7 days | |
Secondary | The length of postoperative hospital stay | Through hospital stay after procedure, an average of 2-7 daysc | ||
Secondary | Total hospital costs of treatment per participants | Through hospital stay after procedure, an average of 2-7 days | ||
Secondary | Eckardt score | The Eckardt score assesses the severity of achalasia symptoms by combining the sum of symptom frequency scores for dysphagia, regurgitation, and chest pain and a weight loss score. Each component can be graded from 0 to 3 points. The total range is 0 to 12, with higher scores indicating more severe symptoms (Eckardt AJ et al, Nat Rev Gastroenterol Hepatol 2011). | baseline, 3 months and 12 months after treatment | |
Secondary | Manometry parameters | Manometry parameters include lower esophageal sphincter (LES) pressure and integrated relaxation pressure (IRP) on high resolution manometry. | baseline and 3 months after treatment | |
Secondary | Maximum esophageal diameter on barium esophagram | baseline and 3 months after treatment | ||
Secondary | Gastroesophageal reflux disease questionnaire (GerdQ) score | The GerdQ has been developed as a tool to facilitate the symptom-based diagnosis of GERD. Scores ranging from 0 to 3 were applied for the four positive predictors (heartburn, regurgitation, sleep disturbance due to reflux symptoms and use of over-the-counter medications for reflux symptoms) and from 3 to 0 for two negative predictors (epigastric pain and nausea). The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. A total GerdQ score >7 is considered indicative of significant GERD symptoms (Jones R et al, Aliment Pharmacol Ther 2009). | baseline, 3 months and 12 months after treatment | |
Secondary | Reflux esophagitis on post-POEM endoscopy | The severity of reflux esophagitis is graded according to the Los Angeles classification (Armstrong D et al, Gastroenterology 1996). | 3 months after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Withdrawn |
NCT02663206 -
Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders
|
N/A | |
Active, not recruiting |
NCT00188344 -
A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia
|
N/A | |
Recruiting |
NCT04578769 -
Assessment of Different Modified POEM for Achalasia
|
N/A | |
Not yet recruiting |
NCT05010889 -
Quality of Life After POEM for Achalasia
|
||
Recruiting |
NCT02572193 -
To Assess the Feasibility of Same Day Discharge Following a POEM Procedure
|
N/A | |
Terminated |
NCT02606578 -
Achalasia Patient Reported Outcomes
|
||
Active, not recruiting |
NCT01750385 -
Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia
|
N/A | |
Active, not recruiting |
NCT03404739 -
Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia
|
Phase 2/Phase 3 | |
Completed |
NCT04112693 -
Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study.
|
N/A | |
Recruiting |
NCT05602272 -
Respiratory and Hemodynamic Implications of Endoscopic Myotomy of the Esophagus and Stomach
|
||
Recruiting |
NCT05113173 -
Study on the Relationship Between Pathological Features of Achalasia and Prognosis of Per-oral Endoscopic Myotomy
|
||
Completed |
NCT00490750 -
Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia
|
N/A | |
Recruiting |
NCT02518542 -
Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia
|
N/A | |
Recruiting |
NCT00260585 -
Esophageal Cancer Risk Registry
|
||
Recruiting |
NCT05899842 -
Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia
|
N/A | |
Completed |
NCT03702647 -
Ropivacaine For Post-POEM Pain Control
|
N/A | |
Recruiting |
NCT01637311 -
Peroral Endoscopic Remyotomy for Failed Heller Myotomy
|
N/A | |
Completed |
NCT00004416 -
Randomized Study of Botulinum Toxin Type A for Achalasia
|
N/A | |
Not yet recruiting |
NCT06027190 -
Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia.
|
N/A |